Could Fingolimod Combined with Bevacizumab Be a New Hope in Glioblastoma Treatment?
Glioblastoma, classified as a grade IV astrocytoma, is an aggressive and malignant primary brain tumor with no known cure. Despite the implementation of standard medical and surgical treatment protocols, the disease often progresses with unsatisfactory outcomes. This study aimed to evaluate the cyto...
Saved in:
Main Authors: | Murat Baloglu, Canan Vejselova Sezer, Hüseyin Izgördü, Ibrahim Yilmaz, Hatice Mehtap Kutlu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-05-01
|
Series: | Current Issues in Molecular Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/1467-3045/47/6/394 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01) -
The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis
by: Alejandro Bruna-Mejías, et al.
Published: (2025-05-01) -
Investigation of the Effects of Fingolimod on the LPS-Induced Inflammatory Response in the HUVEC Cell Line
by: Hamza Halıcı, et al.
Published: (2025-07-01) -
Advanced Targeted Therapeutic Strategies for Glioblastoma Multiforme: Bevacizumab and Its Emerging Nanotechnology-Based Interventions
by: Soner Şahin, et al.
Published: (2024-12-01) -
TREATMENT FOR RECURRENT GLIOBLASTOMA: ARE THERE SUCCESSES?
by: G. I. Kobyakov, et al.
Published: (2015-04-01)